Phase 1, Phase 2, Phase 3, NDA, BLA, PDUFA—drug-development headlines come with a lot of shorthand. Here is a patient-friendly look at how an FDA decision actually happens.

A casual question at a barbecue turned into a bigger conversation about exercise, appetite, weight regulation, and when GLP-1 treatment may be worth discussing.

The first pivotal Phase 3 obesity results for retatrutide are in. At 12 mg, participants lost an average of 28.3% of their starting weight over 80 weeks in TRIUMPH-1.

Novo Nordisk has submitted CagriSema to the FDA for chronic weight management. Here is what this milestone means and what comes next in the review process.

The medical story of GLP-1-based treatment now extends beyond the scale, with medication-specific evidence and FDA indications involving cardiovascular disease, sleep apnea, and metabolic liver disease.

The full REDEFINE 1 Phase 3 results for CagriSema are now published. Here is what the data add beyond the headline weight-loss number.

The first major Phase 3 results for CagriSema are in. The combination of cagrilintide and semaglutide produced up to 22.7% average weight reduction in REDEFINE 1.

Weight management is no longer a one-medication conversation. Lifestyle, medical history, goals, side effects, cost, and long-term planning all matter.

CagriSema combines semaglutide with the amylin analogue cagrilintide. Early combination data suggest that two complementary appetite pathways may produce a different effect than either drug alone.

Retatrutide activates GIP, GLP-1, and glucagon receptors in one molecule. Phase 2 results suggest that adding a third pathway may change what is possible with medication-induced weight loss.

Cagrilintide takes a different path from GLP-1 medications by building on amylin, a hormone involved in satiety. Early Phase 2 data made it a weight-management molecule worth watching.